Jun 01, 2006 · Interpreting the results of plasma human immunodeficiency virus type 1 (HIV-1) genotypic drug-resistance tests is one of the most difficult tasks facing clinicians caring for HIV-1–infected patients. There are many drug-resistance mutations, and they arise in complex patterns that cause varying levels of drug resistance.
the combination of resistance testing and therapeutic drug monitoring is the first step toward a global approach of HIV treatment taking into account the right drug at the appropriate concentration.
Testing drug levels; Testing drug levels. Jump to. patient, and drug. Most studies evaluating relationships between drug levels and virological response included patients who harboured virus that was fully sensitive to the drug of interest. a randomized study of plasma drug measurements in association with genotypic resistance testing
Both baseline genotypic drug resistance and phenotypic drug resistance predicted virological failure, regardless of whether these factors were analyzed separately or were adjusted for other baseline confounding factors (such as plasma HIV-1 RNA level and the number and type of new antiretroviral agents in the regimen).
HIV-1 Drug Resistance Genotype Results in Patients Three thousand six hundred thirty-one genotypic resistance tests and plasma HIV-1 RNA levels were per- logic response was caused by drug resistance that would re-quire a change in therapy.
Objectives: To describe regional differences and trends in resistance testing among individuals experiencing virological failure and the prevalence of detected resistance among those individuals who had a genotypic resistance test done following virological failure. Design: Multinational cohort study.
Low plasma concentrations of PIs can cause viral resistance and treatment failure , and conversely, elevated plasma concentrations may enhance drug toxicity . Given the shared transmission
For robustness analyses, we further distinguished between patients with high-level resistance (level 5) and those with low-level or intermediate resistance (level 3 or 4) to at least one of their drugs.
10.Casado J, Moreno S, Hertogs K, Dronda F, Antela A, Dehertogh P, et al. Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen. AIDS 2002, 16:47–52.
In this study, we sought to ascertain the rate of virological failure (VF), the level of drug resistance mutations and HIV-1 genetic diversity among people living with HIV (PLHIV) receiving first-line ART as per the Chadian AIDS program in N’Djamena.
A genotypic inhibitory quotient (GIQ) was estimated for each patient based on the ratio between LPV trough levels and the number of PRO resistance mutations. A positive strong correlation was found between GIQ and viral load reductions ( r = 0.42; p = 0.002).
Virological response to antiretroviral treatment (ART) in rural Africa is poorly described. We examined virological efficacy and emergence of drug resistance in adults receiving first-line ART for up to 4 years in rural Tanzania. Haydom Lutheran Hospital has provided …
When sufficient plasma was available, we studied HIV-1 genotypic resistance in patients with virological failure by sequencing the protease and reverse transcriptase genes with ViroSeq® 2.0 (Abbott Laboratories, Illinois, USA).
Interpreting the results of plasma human immunodeficiency virus type 1 (HIV-1) genotypic drug-resistance tests is one of the most difficult tasks facing clinicians caring for HIV-1—infected patients. There are many drug-resistance mutations, and they arise in complex patterns that cause varying levels of drug resistance.